

# **Original Research Article**

## **Sero-Epidemiology of Transfusion Transmissible Hepatitis B, C and E among Blood Donors in Ekiti, Southwestern Nigeria: A Cross-sectional Study**

### **ABSTRACT**

**Background:** Transfusion transmissible hepatitis (TTH) is a global health problem and the incriminating agents such as hepatitis B virus (HBV), hepatitis C virus (HCV) and hepatitis E virus (HEV) continue to pose serious threats to blood safety and transfusion recipients. The aim of this study is to determine the seroprevalence of HBV, HCV and HEV and relate the outcomes blood donation type, age and gender and confirm any significant associations.

**Materials and Methods:** Hepatitis B surface antigen (HBsAg) and antibody to HCV were determined with Diaspot and Lab Acon immunochromatographic ELISA-based test devices. Antibodies to HEV were first determined with Biopanda rapid one step lateral flow device followed by ELISA assay for sero-reactive HEV IgM and HEV IgG antibodies.

**Results:** A total of 370 prospective blood donors between 18 and 55 years old (mean  $31.2 \pm 7.6$  years) who presented for blood donation at Federal Teaching Hospital, Ido Ekiti Blood Bank were screened. Male: female ratios among voluntary blood donors (VBD) and replacement blood donors (RBD) were 1:1 and 9:1 respectively. Cumulative hepatitis seroprevalence of 8.1% was found mainly among the RBD and consist of 4.3%, 1.6%, 1.1%, 0.8% and 0.3% serologic evidence of HBsAg, anti-HCV, HEV IgM, HEV IgM & HEV IgG, and HEV IgG antibodies. Blood donors aged 18 – 45 years were most affected and there was significant associations between the age group of donors and TTH seroprevalence ( $P=0.012$ ) Cumulative hepatitis seroprevalence among VBD was 0% while it was of 9.1% and 0.3% among the male and female RBD respectively. No dual infections. There was significant association between the pathogens and RBD ( $P=0.00$ ) and male gender, though the association with male gender was clinically but not statistically significant ( $P=0.06$ ).

**Conclusion:** The high transfusion transmissible hepatitis seroprevalence among RBD pictured the need for promoting voluntary donations. Comparable prevalence of HEV antibodies with that of HCV called for its inclusion in the TTIs screening algorithm to ascertain optimal blood safety in Nigeria.

**Keywords:** Blood donors, Transfusion transmissible hepatitis, Ekiti, COVID-19 pandemic, Sero-epidemiology

## Introduction

Blood transfusion can save millions of lives yet compromise of blood safety quality can expose recipients to danger due to life threatening blood borne infections otherwise referred to as transfusion transmissible infections (TTIs).<sup>1-2</sup> Transfusion transmissible hepatitis (TTH) is a major public health problem that poses threats not only to the recipients of blood transfusion but also their friends and families.<sup>3</sup> Hepatitis B virus (HBV) and hepatitis C virus (HCV) are blood borne infections that are more endemic in Sub-Saharan Africa and Asia when compared to other parts of the world and the roles of stringent screening for these viruses to ensure optimal blood safety cannot be overemphasized.<sup>4</sup> Of recent, hepatitis E virus (HEV) infection has been reported by Traoré et al<sup>5</sup> and Yazbek et al<sup>6</sup> to pose increasing threats to blood safety. Hepatitis E virus is the most common cause of acute hepatitis worldwide.<sup>7-8</sup> Immunocompromised patients transfused inadvertently with hepatitis E virus-infected unit have greater risk of developing chronic hepatitis E virus infection.<sup>9-10</sup> while fatal cases of fulminant hepatitis can result when such units are transfused to pregnant women especially in their third trimester.<sup>11-12</sup> Varying HBV and HCV mono-infection and HBV-HCV dual infection prevalence among blood donors have been reported by authors in Nigeria<sup>13-14</sup> while few authors reported HEV mono-infection among blood donors.<sup>15-18</sup> While the compulsory screening for TTIs has been a constant practice in nearly all health facilities in Nigeria, HEV has not been part of the testing protocol especially in Ekiti state and there is a great possibility of inadvertent transfusion of HEV-infected blood into recipients. We posit that inclusion of HEV in the testing protocol in addition to hepatitis B surface antigen (HBsAg) and anti-HCV screening require scientific approach that ensure availability of baseline data on HEV at the only serving federal tertiary health institution in Ekiti state to assess its blood safety contributions and its possible inclusion in the national database.

Most apparently healthy individuals especially blood donors with hepatitis are in their asymptomatic phases and the challenges of poor health facilities in Sub-Saharan Africa make transfusion of blood a risk.<sup>19</sup> Transfusion of infected blood is very costly from all points of view. From social and psychological points of view, the grave consequences of transfusion associated hepatitis in asymptomatic recipients include high risk to, and high dependency on relative and friends; behavioural changes due to the psychological trauma; marginalization and stigmatization of infected individuals due to fear or cultural reasons, and possible restrictions of access to care or discrimination in some countries of residence.<sup>20-22</sup>

Post-transfusion clinical impacts of HBV<sup>23</sup>, HCV<sup>4</sup> and HEV<sup>7,10</sup> are too challenging for recipients to cope with. These impacts may range from progression to chronicity, high risk of cirrhosis and hepatocellular carcinoma (HCC) and antiviral drug insufficiency<sup>20, 23</sup> thus contributing to high morbidity and mortality rate.<sup>23</sup> Buseri et al<sup>3</sup> listed increased need for medical care, more demand for support, and low service delivery by personnel as the economic costs of failure to control the transmission of TTH and other blood borne infections. That is actually a great burden on already Nigeria-low ranked health and social services and the national economy based on global and country-based findings.<sup>3, 24</sup>

Enhancing optimal blood safety is one of the primary objectives of the World Health Organization.<sup>24</sup> However, achievement of optimal blood safety in Sub-Saharan Africa may be more challenging and requires multiple approaches due to factors contributing to transfusion-related transmissions such as

poor donor selection, high endemicity of TTH in this region, multiple transfusions, inadequate screening facilities, lack of capacity to ensure sustainable operations and other associated risk factors of hepatitis.<sup>3</sup> With the National Blood Service Commission Act 2021 in Nigeria, there is a need to ensure current data availability that will enhance blood transfusion related policy formulations and ease of implementations of same. This study was conducted to determine the prevalence of TTH and possible co-infections among blood donor populations in Ekiti state and provide the baseline data for hepatitis E research and the implementation of National Blood Transfusion Services (NBTS) strategies in the long run.

## **Material and Method**

### **Study population**

A total of 370 apparently healthy prospective blood donors aged between 18 and 55 years (mean age:  $31.2 \pm 7.6$  years) who presented at the Blood Transfusion Laboratory, Federal Teaching Hospital, Ido Ekiti between June, 2020 and January, 2021 and gave written informed consent were selected by consecutive sampling technique. Ido Ekiti is the headquarters of Ido/Osi local government with an estimated population of 106, 792 people. It is located 25km from Ado Ekiti, the state capital, and nearly 376.5km to Abuja. The tertiary hospital serves Ekiti state and the four neighbouring states (Osun, Ondo, Kwara and Kogi states). As at 2015 male and female median age in Ido Ekiti were 18.6 years and 19.7 years respectively and over 17,000 met the age criterion for blood donation.<sup>25</sup> Structured questionnaires were used to obtain the demographic data of study participants. Age bracket of 18 – 65 years, weight > 50 kg, and haemoglobin values of 12.5g/dL and 13.5g/dL for female and male donors respectively were used as inclusion criteria while history or evidence of chronic illness, haemolytic diseases, current experience of fever, recent blood transfusion, recent donation and known HBV, HCV and HEV infection were used as the exclusion criteria for this study. Ethical approval was sought and obtained for the study, with assigned number ERC/2020/06/378A from the Human Research and Ethics Committee of the Federal Teaching Hospital, Ido Ekiti.

### **Sample Collection**

Five millilitres of whole blood samples were collected by venipuncture from 370 blood donors and dispensed into EDTA blood collection tubes following informed consent. Plasma was harvested and aliquot into a separate plain container following centrifugation at 2,500 rpm for 5 minutes. Initial screening for hepatitis B surface antigen (HBsAg), antibodies to HCV and HEV (IgM/IgG) was done immediately using sterile transfer pipettes. For seropositive HEV IgM/IgG cases, plasma samples were transferred into – 40°C deep freezer until analysis by enzyme linked immunosorbent assay (ELISA) assay.

### **Serological assays**

Anti-HCV and HBsAg were detected using Diaspot (Diaspot Diagnostics, USA) and LabAcon (Acon Diagnostics, USA) rapid test devices. Two reactive cases from the two test devices were interpreted as positive results while two non-reactive results were interpreted as negative. Use of known positive and negative controls served as part of quality control measures to optimize quality data. The HEV IgM/IgG rapid test device (Biopanda Diagnostic Limited, UK) was used for the initial detection of HEV antibodies.

Those reactive by HEV IgM/IgG rapid test device were further screened with HEV-IgM and HEV-IgG ELISA kits (Melsin Medical Co. Limited, China) to confirm the results. Analyses were carried out according to the manufacturers' instructions.

### **Statistical Analyses**

Research code was assigned to each questionnaire containing the sociodemographic and analytical data generated for ease of data entry and validation. Statistical Package for Social Sciences version 21 was used to analyze data and results were presented tables and charts. Data were saved into storage devices as back-ups to prevent data loss.

### **Results**

A total of 370 prospective blood donors aged 18 – 55 years (mean age =  $31.2 \pm 7.6$  years) were screened for hepatitis B, C and E within the study period. Table 1 showed that the blood donors were predominantly family replacement blood donors (n=353; 95.4%) and 326 (88.1%) were male donors while 44 (11.9%) were female donors thus giving an approximate male: female ratio of 7:1. Male: female ratio among the voluntary, non-remunerated blood donors (VNBD) and replacement blood donors (RBD) were 1:1 and 9:1 respectively. Highest number of blood donors (n=156; 42.2%) fell within 26-35 years age group. The enrolled blood donors were predominantly Yoruba (n=334; 90.3%); at least 315 (85.0%) had secondary education; and 181 (48.9%) and 183 (49.5%) were singles and married respectively. Nearly two-third (n=245; 66.2%) were self-employed.

Table II revealed a cumulative hepatitis markers seroprevalence of 8.1% as mono-infections while no dual infection was found. According to the serological markers screened, HBsAg, anti-HCV, HEV IgM, HEV IgM & IgG, and HEV IgG seroprevalence were 4.3%, 1.6%, 1.1%, 0.8% and 0.3% respectively. In the cumulative viral hepatitis seroprevalence, HBsAg, anti-HCV, HEV IgM, HEV IgM & IgG, and HEV IgG constituted 53.3%, 20.0%, 13.3% 10.0% and 3.3% respectively. Table III showed that all the seropositive TTH markers occurred among the replacement blood donors (n=30; 8.1%). Table IV showed that male blood donors had cumulative hepatitis seroprevalence of 9.1% while the female counterparts had only 0.3%. Within the male gender, 16 (5.2%), 6 (1.8%), 4 (1.2%), 2 (0.6%) and 1 (0.3%) were seropositive for HBsAg, anti-HCV, HEV IgM, HEV IgM & IgG (HEV antibody total), and HEV IgG markers respectively. Highest number of male blood donors fell within age group 26-35 years (n=138; 42.6%) followed by 18-25 years (n=96; 29.4%) and 36-45 years (n= 82; 25.2%) respectively. Cumulative hepatitis markers seroprevalence were 3.7%, 2.8% and 2.1% among the 26-35 years, 18-25years and 36-45 years age-group male donors respectively. The only female RBD age grouped 36 – 45 years was seropositive for both HEV IgM and IgG antibodies.

### **Discussion**

This study showed that RBD were the predominant group of blood donors (n=353; 95.4%) that participated in the study. Less than 5.0% (n=17; 4.6%) of the donor populations were VNBD. That was a marked reduction of 94.0% from the previous 77.2% voluntary, non-remunerated donations reported in the same facility by Amilo et al<sup>26</sup> in 2017 and over 500% increase in replacement donations. Marked

switch in donation experience reported might not be unconnected with the gross effects of economic meltdown on the country which in turn negatively impacted on the donor drive activities of the facility and the NBTS in the state with which Federal Teaching Hospital had strong collaboration. In essence, funding by the government is a major key factor in the achievement of 100% voluntary, non-remunerated, anonymous donations advocated for by the World Health Organization.<sup>24</sup> Again, it could also be attributed to the unquantifiable havocs wrecked by COVID-19 pandemic on Ekiti state and Nigeria's already overwhelmed blood transfusion services during the ongoing lockdown at the study period (David *et al.*, 2021).<sup>27</sup> The lockdown was accompanied with restricted movements and skeletal activities of NBTS facility in Ekiti state. The United Nations estimated 206,139,589 as the Nigeria's population in 2020<sup>28</sup> and Nigeria's National Blood Service Commission collected 21,780 voluntary blood donations in 2020 according to Oreh *et al.*<sup>29</sup> That translated to 0.01% voluntary donations for that year and it was 100-fold less than 1% of Nigeria population recommended as voluntary blood donors for Nigeria's blood need.<sup>30</sup> Replacement donations thus remained the only feasible solution to severe blood shortages being faced by the country and the need to meet the increased demand for blood due to haemolytic episodes, road traffic accidents, surgical interventions, maternal comorbidities, severe anaemia, haemorrhagic shocks, cancer related issues and other medical conditions. Study showed the need to address the protracted issue of COVID-19 pandemic holistically with considerations to its negative impacts on blood and blood products availability and supply.<sup>27, 29</sup> Another study by Okoroiwu *et al* on voluntary donations during COVID-19 pandemic in Nigeria showed similar trend of negative impacts.<sup>31</sup> Moreover, comparison of male: female ratio among the study participants showed there was no gender disparity among VNBD as was found among the RBD with high male: female ratio (9:1). Oreh *et al*<sup>29</sup> and the World Health Organization<sup>30</sup> reported 33% voluntary non-remunerated donations by women. With more efforts on public enlightenment programmes that break the female gender phobia for blood donation, availability of blood from the safest category of blood donors is a great possibility. The blood donors were predominantly Yoruba and Christian dominated and 85.0% of them had at least secondary education. Amilo and her co-authors reported same findings.<sup>26</sup>

From this study, a cumulative transfusion transmissible hepatitis seroprevalence of 8.1% and 0% dual-infection were found. Hepatitis B virus was the leading cause of TTH in this study as evidenced by 4.3% HBsAg seropositivity. It constituted 53.3% of the cumulative hepatitis markers seroprevalence. All the blood donors were asymptomatic and were unaware of their status until tested. That lent credence to the submission of the Hepatitis B Foundation which stated that more than 90% of infected individuals with hepatitis B virus infection are not diagnosed.<sup>32</sup> Detection of HBsAg in serum or plasma of blood donors over six months is an evidence of chronic carrier or chronic immune active hepatitis B infection.<sup>26</sup> and the seropositive blood donors ran the risk of developing consequent cirrhosis and in advanced cases, hepatocellular carcinoma.<sup>26</sup> HBsAg seroprevalence in this study was lower than 6.2% and 12.0% hepatitis B surface antigenaemia published in 2015 and 2020 by Adekoya-Benson *et al* and Daramola *et al* respectively at the State-owned tertiary health facility.<sup>33-34</sup> The wide difference between HBsAg seroprevalence reported in this study and that of Daramola *et al*<sup>34</sup> could probably be due to differences in the categories of blood donors used and the study design. Retrospective data of replacement and commercial blood donors' were used in the latter study while prospective data of voluntary and replacement blood donors were used in this study. According to the World Health Organization, paid

blood donors do present as RBD to blood bank staff thereby posing more threats to blood safety.<sup>35</sup> Without strict measures in place to checkmate that possibility; it was not unlikely that many of the blood donors were paid donors as revealed by high prevalence of TTIs and consequent high discard rate. Besides, it can cause a sharp difference in WHO viral hepatitis endemicity classification owing to non-conformity with the voluntary donations advocacy. In essence, high endemicity of TTIs in Nigeria and many African countries could be traced to very low level of voluntary donations practice.

Moreover, anti-HCV antibody seropositivity found in this study was 1.6%. Anti-HCV seroprevalence in this study was similar to 1.7% reported by Adekoya-Benson et al<sup>33</sup> in Ekiti state tertiary health facility in 2015. It was lower than 6.7% recently reported by Daramola et al<sup>34</sup> in the same facility in Ekiti, 3.6% reported by Okoroiwu et al<sup>31</sup> in Calabar and 6.0% reported by Buseri et al<sup>3</sup> in Osogbo respectively. However, it was higher than pooled seroprevalence of 0.8% reported by Lake et al<sup>36</sup> in a systematic and meta-analysis review among blood donors in Ethiopia and 0.39% reported by Macroo et al<sup>37</sup> in India. Anti-HCV seroprevalence of 0.5% have been reported by Erhabor et al<sup>38</sup> in Port-Harcourt. The differences in anti-HCV seroprevalence in this study and others confirm the variations in HCV endemicity in different parts of Nigeria.

Based on Hepatitis E viral markers seropositivity, overall HEV seroprevalence in this study was 2.4%. In different parts of the globe, authors<sup>39-40</sup> have shown in surveillance studies that seropositivity of HEV among blood donors ranged from 2% to 49%.<sup>41</sup> The HEV IgM antibody seroprevalence of 1.1% reported in this study is lower than 5.0%, 5.9% and 1.3% seroprevalence reported by Al-Kasaby et al<sup>39</sup> in Egypt, Meldal et al<sup>42</sup> in Ghana and John-Olabode et al<sup>16</sup> in Nigeria respectively. It was approximately two-to-five-fold higher than 0.5, 0.4% and 0.2% seroprevalence reported by Spada et al<sup>43</sup> in Italy, Ibrahim et al<sup>44</sup> in Egypt and Ma et al<sup>45</sup> in China respectively. HEV IgM antibody detection is the hallmark of acute hepatitis infection.<sup>46</sup> There is a virtual lack of published data on simultaneous sero-detection of HEV IgM and HEV IgG in Ekiti state and Nigeria. This study therefore provides a baseline seroprevalence with which multicenter studies among blood donors can be compared and used for national policy formulations. A seroprevalence and incidence study carried out in Upper Austria among blood donors on follow up showed both HEV IgM and HEV IgG antibodies were detected in 6 of 7 (85.7%) blood donors tested 2-11 weeks post-donation.<sup>47</sup> All were previously seronegative for both HEV antibody markers at donation period and had detectable molecular marker (HEV RNA). That agreed with a recent study by Traore et al<sup>6</sup> that emphasized HEV increasing threat to blood safety and other studies that reported post-transfusion hepatitis E infection in transfusion recipients.<sup>9, 17</sup> HEV IgG antibody seroprevalence in this study is 0.3%, translating to 3 per 1000 blood donors. This is lower than 3.14% seroprevalence reported by Al Dossary et al<sup>41</sup> among male donors in Saudi Arabia. HEV IgG is the evidence of past infection. Variations in HEV IgG antibody seroprevalence worldwide have been attributed to differences in sensitivities, specificities and limit of detection of assay kits, geographical locations, poor quality control measures and population tested<sup>16, 46</sup>. The enzyme-linked immunosorbent assay kit used for this study demonstrated high sensitivity and specificity (data not shown) which shows truly low HEV IgG antibody seroprevalence in this study. A previous vaccine study showed that HEV IgG antibody confers immune protection to once exposed and immune patients and an anti-HEV IgG titre of 2.5 IU/mL is protective.<sup>48</sup>

Evidence from this study showed that viral hepatitis seroprevalence is somewhat male gender and blood donor type associated. Distribution of blood donors based on gender, age group and viral hepatitis seroprevalence showed that the numbers of both male and female blood donors peaked at age group 26 – 35 years with 139 (42.6%) and 17 (38.6%) enrolled in the study. More than 99% of the HBsAg seropositive (4.9%) male donors and 100.0% of seropositive anti-HCV (1.8%) and HEV IgM (1.2%) male blood donors ranged from 18 – 45 years old. This agrees with anti-HCV seroprevalence by Egah et al<sup>49</sup> where all the blood donors were males. There should more risk assessment evaluations among males within this age range to prevent post-transfusion hepatitis in transfusion recipients. Transfusion transmissible hepatitis was predominantly noted among male replacement blood donors with cumulative hepatitis seroprevalence of 9.1%. This is consistent with high transfusion transmissible infections among male donors compared to the female counterparts reported in Calabar.<sup>31</sup> Broadly speaking, the highest rate of TTH occurs among male donors within 18-45 years old. This correlate with previous report by the Centre for Disease Control and Prevention<sup>50</sup> and Buseri et al<sup>3</sup> that found highest rate of TTIs among blood donors of age groups 20-49 years old and 18-47 years old respectively. The highest HBsAg seroprevalence was found among male donors 26-35 years, followed by 36-45 years and 18-25 years respectively. The trend was different for HCV antibody seroprevalence. The anti-HCV antibody seroprevalence declined with increasing age specifics. Younger male blood donors with highest HCV antibody seroprevalence (0.9%) belonged to age group 18-25 years and the oldest male donors within 46-55 years had the least (0.0). This trend was also observed in a north Indian study by Makroo et al.<sup>37</sup>

Seroprevalence of TTH was 0.3% among female blood donors in this study. The only female blood donor with HEV IgM + HEV IgG antibody seroprevalence of 0.3% was a RBD. In other words, irrespective of age group and blood donor type, 99.7% of female blood donors were free from TTH. A number of reasons have been attributed to this near zero seroprevalence. First was optimal blood donor selection. A large percentage of the female blood donors were known VNBD and college students on practical posting who on compassionate ground donated for patients having difficulties in replacing loaned units during the COVID-19 pandemic era. That again agreed with the well-established fact that voluntary donation is the ethical and international best practice to achieve optimal blood safety.<sup>24</sup> Secondly administration of questionnaires for clinical assessments prior donation helped more in excluding female volunteers who had the potential risk of TTH. This study revealed the contribution of quality pre-donation counselling in achieving optimal blood safety.

## **Conclusion**

Transfusion transmissible hepatitis is still a global health problem and demands increasing attention for more stringent screening of blood and blood products. Blood and blood products availability and supply from the safest category of blood donors is an important step to ending paid donation system characterized with high TTH. There should be a paradigm shift from the old blood donor recruitment

strategy involving post-donation testing after acceptable haemoglobin value to include emergency screening for TTIs using validated high sensitive and specific rapid ELISA-based kits during exercise prior more advanced procedure. There is an increasing evidence to inculcate HEV antibodies screening into blood donation screening protocol and more elaborate researches among the age-matched general populace as the sexually active blood donors in Nigeria are still required. It is important to point out that study outcomes and others on TTIs in Nigeria and across the globe show there is need for more quality controls of blood banking practices in Nigeria and Africa by extension in order to standardize quality of blood and minimize, if not totally eradicate, post-transfusion TTHs in recipients.

#### **COMPETING INTERESTS DISCLAIMER:**

**Authors have declared that no competing interests exist. The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.**

#### **References**

1. Farshadpour F, Taherkhani R, Tajbakhsh S, Gholizadeh Tangestani M, Hajiani G, Sharifi N, et al. Prevalence and Trends of Transfusion-Transmissible Viral Infections among Blood Donors in South of Iran: An Eleven-Year Retrospective Study. PLoS ONE 2016; 11(6): e0157615.
2. Bartongo G, Oundo J, Ng'ang'a Z. Prevalence and associated risk factors of transfusion transmissible infections among blood donors at Regional Blood Transfusion Center Nakuru and Tenwek Mission Hospital, Kenya. The Pan African Medical Journal. 2019; 34: 31 – 43.
3. Buseri FI, Muhibi MA, Jeremiah ZA. Sero-epidemiology of transfusion transmissible infectious diseases among blood donors in Osogbo, South-west, Nigeria. Blood Transfusion. 2009; 7(4): 293-299.
4. Shamsizadeh A, Hassanshahiraviz G, Arababadi MK, Assar S, Hakimi E, Ayoubi F. Post-transmitted hepatitis C virus infection: a study on thalassemia and hemodialysis patients in southeastern Iran. International Journal of Infectious Diseases; 2012, 16S(1): e2-e157.

5. Traoré KA, Ouoba JB, Rouamba H, Nébié YK, Dahourou H, Rossetto F et al. Hepatitis E Virus Prevalence among Blood Donors, Ouagadougou, Burkina Faso. *Emerging Infectious Diseases*. 2016; 22 (4): 755-57.
6. Yazbek S, Kreidieh K, Ramia S. Hepatitis E virus in the countries of the Middle East and North Africa region: an awareness of an infectious threat to blood safety. *Infection* 2016; 44:11–22.
7. Rui Z, Jiang L, Wang X, Yang Y, Peng Y, Ling Y et al. Prevalence of hepatitis E virus infection among pregnant women in Zhenjiang, China. *Frontiers in Laboratory Medicine*. 2018; 2(2018): 116-119.
8. Anastasiou OE, Thodou V, Berger A, Wedemeyer H, Ciesek S. Comprehensive Evaluation of Hepatitis E Serology and Molecular Testing in a Large Cohort. *Pathogens*. 2020, 9, 137-147.
9. Matsubayashi K, Kang J-H, Sakata H, Takahashi KK, Shindo M, Kato M et al., “A case of transfusion-transmitted hepatitis e caused by blood from a donor infected with hepatitis e virus via zoonotic food-borne route,” *Transfusion*. 2008; 48 (7):1368–75. Thakur V, Ratho RK, Kumar S, Saxena SK, Bora I, Thakur P. Viral hepatitis E and Chronicity: A growing Public Health Concern. *Front Microbiol*. 2020; 29:11:577339.
10. Thakur V, Ratho RK, Kumar S, Saxena SK, Bora I, Thakur P. Viral Hepatitis E and Chronicity: Growing Public Health Concern. *Frontiers in Microbiology Virology*. 2020; 11(577339):1-18.
11. Bouthry E, Benachi A, Vivanti AJ, Letamendia E, Vauloup-Fellous C, Roque-Afonso A-M. Autochthonous Hepatitis E during Pregnancy. *Emerging Infectious Diseases*. 2018; 24 (8):1586 – 1587.
12. Dagne M, Belachew A, Tiruneh M, Moges F. Hepatitis E virus infection among pregnant women in Africa: systematic review and meta-analysis. *BMC Infectious Diseases*. 2019: 519 (2019):1-14 World Health Organization. Hepatitis B key Facts. 2021. Available at: [www.who.int/health-topic/hepatitis#tab=tab\\_1](http://www.who.int/health-topic/hepatitis#tab=tab_1). (Accessed on 27<sup>th</sup> January 2021).
13. Kassim OD, Oyekale TO, Anekeo JC, Durosimi MA. Prevalence of Seropositive Blood Donors for Hepatitis B, C and HIV viruses at Federal Medical Centre, Ido Ekiti, Nigeria. *Annals of Tropical Pathology*. 2012; 3 (1): 47-55.
14. Gowda A. Prevalence of Hepatitis B and C among Blood Donors in Makurdi, Benue State, Nigeria. *The International Journal of Science & Technoledge* 2014; 2(3): 248-254

15. Boxall E, Herborn A, Kochethu G, Pratt G, Adams D, Ijaz S et al. Transfusion- transmitted hepatitis E in a nonhyperendemic country. *Transfus Med* 2006; 16: 79-83.
16. John-Olabode SO, Ajie O, Osunkalu V, Akinbami A, Aile K. Prevalence of anti-HEV among Blood Donors in Lagos, Nigeria, A Pilot Study. *The Journal of Medical Research*. 2017; 3 (4): 203-207.
17. Coilly A, Haim-Boukobza S, Roche B, et al. Post transplantation hepatitis E: transfusion-transmitted hepatitis rising from the ashes. *Transplantation* 2013; 96: e4-e6.
18. Zia M, Ricci C, Taha HM. Transfusion-Transmitted Diseases. Available at: [www.emedicine.medscape.com/article/1389957-overview#a1](http://www.emedicine.medscape.com/article/1389957-overview#a1) (Accessed on 24<sup>th</sup> January 2022).
19. Falla AM, Veldhuijzen IK, Ahmad AA, Levi M, Richardus JH. Limited access to hepatitis/C treatment among vulnerable risk populations: an expert survey in six European countries. *European Journal of Public Health*. 2017; 27 (2): 302 – 306.
20. Yildiz LE, Bahceci L, Yahvuz AY, Kostakoglu U, Ertürk A. Assessment of Stigma Exposure Status of Patients with Hepatitis B Infection. *Viral Hepatitis Journal*. 2021; 27(2):80-88
21. Hepatitis B Foundation. Hepatitis B Facts and Figures. Available at: [www.hepb.org/what-is-hepatitis-b/what-is-hepb/facts-and-figures/](http://www.hepb.org/what-is-hepatitis-b/what-is-hepb/facts-and-figures/) (Accessed on 1<sup>st</sup> February 2021).
22. Kilonzo SB, Daniel Gunda D, Ning Q, Meifang Han M. Where Hepatitis B and Hepatitis E Meet: Epidemiological and Clinical Aspects. *Hepat Mon*. 2019; 19(10):e93840.
23. Fullman N, Yearwood J, Abay SM, Abbafati C, Abd-Allah F, Abdela J et al. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study. *The Lancet*. 2018; 391 (10136):2236 – 2271.
24. World Health Organization. Blood transfusion safety [homepage on the internet], 2021. Available from [https://www.who.int/bloodsafety/voluntary\\_donation/en/](https://www.who.int/bloodsafety/voluntary_donation/en/) (Accessed on February 23, 2022).
25. City-Facts. Ido Ekiti Population. City-Facts 2019-2020. Available at: [www.city-facts.com/ido-ekiti](http://www.city-facts.com/ido-ekiti) (Accessed on March 16, 2022).

26. Amilo GI, Ifeanyichukwu MO, Fasakin KA. Advancing Hepatitis B Virus Testing in Prospective Blood Donors Beyond Current Single Marker Rapid Technique: Is it a Luxury or Necessity? *International STD Research and Reviews*. 2017; 5(2): 1-13.
27. David KB, Simfukwe K, Musa MB, Munharo S, Lucero-Prisno III DE. Impacts of COVID-19 on blood donation and supply in Africa. *African Journal of Laboratory Medicine*. 2021; 10 (1): 1-3.
28. Worldometer. Population of Nigeria (2020 and historical), 2022. Available at: [www.worldometers.info/world-population/nigeria-population/](http://www.worldometers.info/world-population/nigeria-population/) (Accessed on February 24, 2022).
29. Oreh AC, Irechukwu C, Biyama F, Nnabuihe A, Ihimekpen A, Oshiamé D et al. COVID-19 impact on Nigeria's national blood service commission: Lessons for Low- and Middle-Income Countries (LMICs). *Nigerian Postgraduate Medical Journal* 2022; 29:6 – 12.
30. World Health Organization. Hepatitis B key Facts. 2020. Available at: [www.who.int/news-room/fact-sheets/detail/hepatitis-b](http://www.who.int/news-room/fact-sheets/detail/hepatitis-b) (Accessed on 1<sup>st</sup> February 2021)
31. Okoroiwu HU Okafor IM, Asemota EA, Okpokam DC. Seroprevalence of transfusion-transmissible infections (HBV, HCV, syphilis and HIV) among prospective blood donors in a tertiary health care facility in Calabar, Nigeria; an eleven years evaluation. *BMC Public Health*. 2018; 18:645 – 652.
32. Hepatitis B Foundation. Know your right. Immigration and International Issues. Available at: [www.hepb.org/resources-and-support/know-your-rights/immigration-and-international-issues/](http://www.hepb.org/resources-and-support/know-your-rights/immigration-and-international-issues/) (Accessed on 24th January, 2022)
33. Adekoya-Benson T, Famoni PF, Ajala O, Akinbolaji TJ, Adeosun OC, Prevalence of HBV, HCV and Syphilis among the People of Ekiti in South-Western Nigeria. *International STD Research & Reviews*. 2015; 3(2): 40-44.
34. Daramola O, Edogun H, Alex-Abiodun O, Umukoro QM, Ojerinde OA, Ajayi OD et al. Transfusion Transmitted Infections among Blood Donors at a Tertiary Health Facility in Southwest, Nigeria. *Journal of Advances in Microbiology*. 2020; 20 (4): 66-69.
35. World Health Organization. Towards 100% Voluntary Blood Donation: A Global Framework for Action. 2010. Available at: <https://ncbi.nlm.nih.gov/books/NBK305666/> (Accessed on March 7<sup>th</sup> 2022)

36. Lake EA, Fite RO, Gebrekirstos LG, Gebremeghin MH, Obsa MS, Gelaw KA. Seroprevalence of hepatitis c virus among blood donors in Ethiopia: a systematic review and meta-analysis. *BMC Infectious Diseases*. 2021; 131: 1-11.
37. Macroo RN, Walia RS, Chowdhry M, Bhatia A, Hegde V, Rosamma NL. S Seroprevalence of anti-HCV antibodies among blood donors of North India. *The Indian Journal of Medical Research*. 2013; 138 (1): 125-128.
38. Erhabor O, Ejele OA, Nwauche CA. The risk of transfusion-acquired hepatitis-C virus infection among blood donors in Port Harcourt: the question of blood safety in Nigeria. *Nigerian Journal of Clinical Practice*. 2006; 9(1): 18-21.
39. Al-Kasaby NM, Zaki MES. Study of hepatitis E virus in blood donors. *Open Microbiol J*. 2019;13(1):285–291. doi: 10.2174/187428 580191301028523
40. World Health Organization. Global status report on blood safety and availability, 2016; 2017. Available from: [http://apps.who.int/iris/bit\\_stream/10665/254987/1/9789241565431-eng.pdf](http://apps.who.int/iris/bit_stream/10665/254987/1/9789241565431-eng.pdf) (Accessed March 9, 2022).
41. Al Dossary RA, Alnafie AN, Aljaroodi S, Rahman JU, Hunasemarada BC, Alkaharsah KR. Prevalence of Hepatitis E Virus Infection Among Blood Donors in the Eastern Province of Saudi Arabia. *Journal of Multidisciplinary Healthcare*. 2021; 14: 2381–2390.
42. Meldal BHM, Sarkodie F, Owusu-Ofori S, Allain J-P. Hepatitis E virus infection in Ghanaian blood donors - The importance of immunoassay selection and confirmation. *Vox Sang*. 2013;104 (1):30–36. doi:10.1111/j.1423-0410.2012.01637.x52
43. Spada E, Pupella S, Pisani G, et al. A nationwide retrospective study on prevalence of hepatitis E virus infection in Italian blood donors. *Blood Transfusion*. 2018; 16 (5):413–421. doi:10.2450/2018.0033-18.
44. Ibrahim EH, Abdelwahab SF, Nady S, et al. Prevalence of anti-HEV IgM among blood donors in Egypt. *Egypt J Immunol*. 2011;18 (2):47–58
45. Ma L, Sun P, Lin F, et al. Prevalence of hepatitis E virus in Chinese blood donors. *J Int Med Res*. 2015; 43(2):257–262. doi:10.1177/ 0300060514562054
46. Kamar N, Dalton HR, Abravanel F, Izopetb J. Hepatitis E Virus Infection. *Clinical Microbiology Reviews* 2014; 27 (1)116 – 138.
47. Fischer C, Hofmann M, Danzer M, Hofer K, Kaar J, Gabriel C. Seroprevalence and incidence of hepatitis E in blood donors in Upper Austria. *PLoS One*. 2015;10(3):e0119576.

48. Shrestha MP, Scott RM, Joshi DM, Mammen MP, Jr, Thapa GB, Thapa N, Myint KS, Fourneau M, Kuschner RA, Shrestha SK, David MP, Seriwatana J, Vaughn DW, Safary A, Endy TP, Innis BL. Safety and efficacy of a recombinant hepatitis E vaccine. *N. Engl. J. Med.* 2007;356:895–903.
49. Egah DZ, Mandong BM, Iya D et al. Hepatitis C virus antibodies among blood donors in Jos, Nigeria. *Annals of African Medicine.* 2004; 3:35-37.
50. Centre for Disease Control and Prevention. Digestive Diseases and Hepatitis B. Hepatitis Health Center; 2007.

**Table I: Social Demographic Characteristics of Research Participants**

Demographic Variables	Mean Age ( $\pm$ Standard Deviation)	Number (Percentage)
<b>Overall Number of Prospective Blood Donors Screened</b>	31.2 $\pm$ 7.6	370 (100.0)
Voluntary Blood Donors		17 (4.6)
Replacement Blood Donors		353 (95.4)
<b>Sex</b>		
Male		326 (88.1)
Female		44 (11.9)
Male: Female Ratio: <b>7:1</b>		
<b>Sex Based on Donor Category:</b>		
<b>Voluntary Blood Donors:</b>		
Male		17 (4.6)
Female		8 (2.2)
Male: Female Ratio: <b>1:1</b>		9 (2.4)
<b>Replacement Blood Donors:</b>		353 (95.4)
Male		318 (89.8)
Female		35 (5.6)
Male: Female Ratio: <b>9:1</b>		
<b>Age Groups:</b>		
18 – 25	22.6 $\pm$ 2.3	107 (28.9)
26 – 35	30.9 $\pm$ 2.9	156 (42.2)
36 – 45	40.1 $\pm$ 3.2	97 (26.2)

46 - 55	48.1 ± 3.0	10(2.7)
<b>TRIBE:</b> Yoruba Igbo Hausa Ebira Others		334 (90.3) 17 (4.6) 2 (0.5) 7 (1.9) 10 (2.7)
<b>Religion:</b> Christianity Islam		343 (92.7) 27 (7.3)
<b>Educational Status:</b> None Primary Secondary Tertiary		15 (4.1) 40 (10.8) 117 (31.5) 198 (53.5)
<b>Marital Status:</b> Single Married Divorced Separated		181 (48.9) 183 (49.5) 02 (0.5) 04 (1.0)
<b>Occupation:</b> Students Civil Servants Self-employed Poultry Farming Livestock farming		17 (4.6) 103 (27.8) 245 (66.2) 3 (0.8) 2 (0.6)

<b>Table II: Seroprevalence of transfusion transmissible hepatitis markers in the study population</b>				
<b>Viral Hepatitis Marker</b>	<b>Mono-infection</b>		<b>Dual Infection</b>	
	<b>Number (%)</b>		<b>Viral Hepatitis Markers</b>	<b>Number (%)</b>
<b>HBsAg</b>	<b>16 (4.3)</b>		<b>HBsAg – Anti-HCV</b>	<b>0 (0)</b>
<b>Anti-HCV</b>	<b>06 (1.6)</b>		<b>HBsAg – HEV IgM</b>	<b>0 (0)</b>
<b>HEV IgM</b>	<b>04 (1.1)</b>		<b>HBsAg – HEV IgG</b>	<b>0 (0)</b>
<b>HEV IgM &amp; IgG</b>	<b>03 (0.8)</b>		<b>Anti-HCV – HEV IgM</b>	<b>0 (0)</b>
<b>HEV IgM &amp; IgG</b>	<b>01 (0.3)</b>		<b>Anti-HCV – HEV IgG</b>	<b>0 (0)</b>
<b>TOTAL</b>	<b>30 (8.1)</b>		<b>TOTAL</b>	<b>0 (0)</b>

**Key:** %=Percentage HBsAg = Hepatitis B surface antigen; HCV= Hepatitis C Virus;

HEV = Hepatitis E Virus; IgG = Immunoglobulin G;  
 IgM= Immunoglobulin M; HEV IgM & IgG = HEV antibody total

<b>Table III: Seroprevalence of transfusion transmissible hepatitis markers in the Study Population According to Blood Donor Type</b>				
<b>Voluntary Blood Donors</b>		<b>Replacement Blood Donors††</b>		
Hepatitis Markers	Number (%)	Hepatitis Markers	Number (%)	Number Seropositive/30
<b>HBsAg</b>	0 (0)	<b>HBsAg</b>	16 (4.3)	16 (53.3)
<b>Anti-HCV</b>	0 (0)	<b>Anti-HCV</b>	6 (1.6)	6 (20.0)
<b>HEV IgM</b>	0 (0)	<b>HEV IgM</b>	4 (1.1)	4 (13.3)
<b>HEV IgM &amp; IgG</b>	0 (0)	<b>HEV IgM &amp; IgG</b>	3 (0.8)	3 (10.0)
<b>HEV IgG</b>	0 (0)	<b>HEV IgG</b>	1 (0.3)	1 (3.3)
<b>TOTAL</b>	0 (0)	<b>TOTAL</b>	<b>30 (8.1)</b>	<b>30 (100.0)†</b>

Keys: HBV = Hepatitis B Virus  
 HCV= Hepatitis C Virus  
 HEV = Hepatitis E Virus  
 IgG = Immunoglobulin G  
 IgM= Immunoglobulin M

† = Approximated percentage  
 ††= P value= 0.012

**Table IV: Distribution of Blood Donors and Prevalence of Viral Hepatitis B, C and E Based on Gender Within Different Age Groups**

Age (Years)††	Male† Number	Percent	HBsAg	Anti-HCV	HEV IgM	HEV IgM & IgG	HEV IgG	Cummulative Hepatitis Prevalence
18 - 25	96	29.4	3 (0.9)	3(0.9)	2 (0.6)	0 (0.0)	1 (0.3)	9 (2.8)
26 – 35	139	42.2	9 (2.8)	2 (0.6)	1 (0.3)	0 (0.0)	0 (0.0)	12 (3.7)
36 – 45	82	25.2	4 (1.2)	1 (0.3)	1 (0.3)	2 (0.6)	0 (0.0)	7 (2.1)
46 – 55	9	2.8	1 (0.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)
<b>Total</b>	<b>326</b>	<b>(100.0)</b>	<b>16 (5.2)</b>	<b>6 (1.8)</b>	<b>4 (1.2)</b>	<b>2 (0.6)</b>	<b>1 (0.3)</b>	<b>29 (9.1)</b>

  

Age (Years)	Female Number	Percent	HBsAg	Anti-HCV	HEV IgM	HEV IgM & IgG	HEV IgG	Cummulative Hepatitis Seroprevalence
18 - 25	11	25.0	0 (0)	0(0)	0(0)	0(0)	0(0)	0(0)
36 – 45	15	34.1	0 (0)	0 (0)	0(0)	1 (0.3)	0 (0)	1 (0.3)
46 – 55	1	2.3	0 (0)	0 (0)	0(0)	0(0)	0(0)	0(0)
<b>Total</b>	<b>44</b>	<b>(100.0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0(0)</b>	<b>0(0)</b>	<b>0 (0)</b>	<b>1 (0.3)</b>

Keys: HBV = Hepatitis B Virus, HCV= Hepatitis C Virus, HEV = Hepatitis E Virus, IgG = Immunoglobulin G, IgM= Immunoglobulin M; HEV IgM & IgG = HEV antibody total

† P value=0.06 (Non-significant association of Cummulative Hepatitis Seroprevalence with male gender)

†† P= 0.000 (Significant association of Cummulative Hepatitis seroprevalence with age)

UNDER PEER REVIEW